| abstract |
The invention relates to a compound sulfadiazine suspension. The compound sulfadiazine suspension is composed of the following components: 10-40 parts of sulfadiazine, 2-8 parts of trimethoprim micropowder, 0.1-2 parts of cosolvent, 0.1-2 parts of suspension, 0.1-6 parts of anti-caking agent, 1-10 parts of wetting agent, 0.5-5 parts of pH adjusting agent, 0.1-0.5 part of preservative, and 50-80 parts of diluent. The compound sulfadiazine suspension of the invention has the characteristics of not easy to settle, good redispersibility, longer and more stable maintenance time, less or even no crystallization in urinary tract after continuous administration for 5 days, and solves the problem of physical stability in storage in the prior art Poor performance, poor absorption, and serious urinary tract crystallisation problems with continuous use. |